Literature DB >> 27765941

Regulatory watch: Innovative drug availability in China.

Liming Shao1, Lili Xu2, Qiu Li2, Ranjana Chakravarthy3, Ziling Yang3,4, Kenneth I Kaitin3.   

Abstract

Mesh：

Year:  2016        PMID： 27765941     DOI： 10.1038/nrd.2016.200

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

1.  Research and development of mAb drugs in China: a look from policy perspectives.

Authors:  Rong Jiang; Yuanyuan Sun; Carolina Ung; Xinyue Dong; Xiangjun Kong; Yuanjia Hu; Rong Shao
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

2.  Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.

Authors:  Chunrui Bo; Tianqi Wang; Chengbei Hou; Jinming Han; Lixia Chen; Huixue Zhang; Lihua Wang; Hongyan Li
Journal:  CNS Neurosci Ther       Date:  2022-06-01       Impact factor: 7.035

3.  Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers.

Authors:  H Kim Lyerly; Jun Ren; Renzo Canetta; Gi Hyun Kim; Sumimasa Nagai; Tomohiro Yamaguchi; Ken Hatogai; Hiroshi Katayama; Silvy Da Rocha Dias; Daniel McManus; Kathy Soltys; Zhimin Yang; Olufumilayo Olopade; Nancy Goodman; Greg Reaman; Thomas Gross
Journal:  J Glob Oncol       Date:  2018-12

4.  The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review.

Authors:  Haizhu Chen; Yu Zhou; Xiaohong Han; Yuankai Shi
Journal:  Lancet Reg Health West Pac       Date:  2021-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.